Risk For Major Bleeding In Patients With HIV Infection And Atrial Fibrillation On ART Is Higher With Use Of Warfarin And Rivaroxaban Than With Apixaban, Research Indicates

Infectious Disease Advisor (5/14, Nye) reports, “The risk for major bleeding in patients with HIV infection and atrial fibrillation (AF) on antiretroviral therapy is higher with the use of warfarin and rivaroxaban than with apixaban, highlighting the superior safety profile of apixaban in high-risk HIV populations.” Investigators came to this conclusion after evaluating “patients aged 50 years and older with HIV and AF who initiated anticoagulant therapy with warfarin, rivaroxaban, or apixaban between 2013 and 2020 for major bleeding-associated hospitalization.” The findings were published in JAMA Internal Medicine.